.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The medical community is rapidly adopting long-acting therapeutics maternal pediatric solutions to overcome chronic adherence barriers. However, pregnant women, breastfeeding mothers, and children often face significant delays in accessing these innovative treatments. A recent white paper from the University of Liverpool Centre of Excellence for Long-acting Therapeutics (CELT) addresses these historical disparities. This document synthesizes findings from a July 2025 global workshop focused on bridging research and access gaps.
Currently, clinical research designs frequently exclude special populations, leading to a scarcity of safety and efficacy data. Consequently, the white paper advocates for inclusive and context-sensitive research protocols. Furthermore, clinicians and researchers must push for harmonized regulatory frameworks that recognize the unique physiological needs of infants and pregnant individuals. Establishing these standards will accelerate the deployment of long-acting formulations in diverse clinical settings.
Sustainable funding remains a critical bottleneck for pediatric drug development. Therefore, the report emphasizes the need for interdisciplinary collaboration among academia, the pharmaceutical industry, and public health organizations. Additionally, culturally responsive implementation strategies are vital to ensure that new therapies reach the most vulnerable populations. Such partnerships will be central to realizing the full potential of long-acting technologies globally.
Long-acting therapeutics reduce the daily pill burden, which significantly improves treatment adherence and quality of life for children with chronic conditions.
Harmonization aligns safety standards across different countries. This alignment allows faster access to life-saving medications for pregnant women who are often excluded from early clinical trials.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Archary M et al. A White Paper on Advancing Long-Acting Therapeutics for Maternal and Pediatric Health by Bridging Gaps in Clinical Research, Access and Regulation. Clin Pharmacol Ther. 2026 Apr 14. doi: 10.1002/cpt.70288. PMID: 41981739.
O'Connor McFerran and Quinney Page. Bridging the Gap: Inclusion of Pregnant Women in Clinical Drug Trials. Clin Chem. 2025; 71(1): 1-5.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A 2025 white paper outlines strategies to improve access to long-acting therapeutics for pregnant women and children through research and regulation....
4 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
